Key Points
Analysts expect $0.925 EPS and $10.99B revenue on May 6.
NONOF likely beats EPS but misses revenue based on historical patterns.
Stock trades 46% below 52-week high at $44.35, offering potential value.
Meyka AI rates NONOF B+, reflecting solid profitability but growth execution risks.
Novo Nordisk A/S (NONOF) reports earnings on May 6, 2026, with analysts expecting $0.925 EPS and $10.99 billion in revenue. The Danish pharmaceutical giant faces a critical test as investors monitor its diabetes and obesity care divisions. Recent quarters show mixed performance, with the company beating EPS estimates but missing revenue targets. At $44.35 per share, NONOF trades near its 50-day average, reflecting cautious investor sentiment. The $197.6 billion market cap company must demonstrate sustained growth in its high-margin GLP-1 product lines to justify current valuations.
Earnings Estimates and Historical Performance
Analysts project $0.925 EPS and $10.99 billion revenue for the upcoming earnings report. This represents a modest decline from recent quarters, signaling potential headwinds in the pharmaceutical sector.
Recent Quarter Comparisons
Novo Nordisk’s last four quarters show inconsistent results. In February 2026, the company beat EPS estimates ($0.946 actual vs. $0.922 expected) but exceeded revenue expectations ($12.39B actual vs. $11.86B estimated). August 2025 results were stronger, with $0.94 EPS and $12.13B revenue, though both slightly missed estimates. May 2025 showed the strongest EPS beat at $0.961 versus $0.885 expected, but revenue fell short at $11.49B versus $11.96B estimated. This pattern suggests NONOF prioritizes profitability over top-line growth.
Beat or Miss Prediction
Based on historical trends, NONOF likely beats EPS but misses revenue. The company has beaten EPS in three of four recent quarters while missing revenue in two of four. Current estimates of $0.925 EPS appear conservative relative to recent performance, suggesting potential upside. However, revenue guidance of $10.99B seems optimistic given recent quarterly trends averaging $11.76B.
Key Metrics and What to Watch
Investors should focus on specific operational metrics that drive Novo Nordisk’s valuation and future growth prospects.
Diabetes and Obesity Care Division Performance
This segment represents NONOF’s growth engine, particularly GLP-1 products like Ozempic and Wegovy. Watch for volume growth, pricing power, and market share gains in obesity treatment. The company’s $10.99B revenue estimate depends heavily on sustained demand for these high-margin products. Any slowdown in obesity care adoption or increased competition from Eli Lilly could pressure results.
Operating Margins and Cash Flow
Novo Nordisk maintains impressive 33.14% net profit margins and 38.55% operating cash flow ratios. Investors should monitor whether margins expand or contract amid manufacturing costs and R&D investments. The company’s $26.80 operating cash flow per share and $12.65 free cash flow per share fund its 4.14% dividend yield, making cash generation critical for shareholder returns.
Geographic and Product Mix
Analysts will scrutinize revenue breakdown by region and product category. International markets, particularly Europe and emerging economies, face pricing pressure. Watch for commentary on oral GLP-1 candidates and hemophilia product performance, which diversify revenue streams beyond obesity care.
Valuation and Market Context
NONOF trades at a 12.32 P/E ratio, below historical averages, reflecting recent stock weakness and investor caution about growth sustainability.
Valuation Multiples Analysis
The 4.08 price-to-sales ratio and 6.52 price-to-book ratio suggest moderate valuation relative to peers. However, the 22.45 price-to-free-cash-flow ratio indicates investors pay premium prices for cash generation. At $44.35, the stock trades 46% below its 52-week high of $82.50, creating potential value for long-term investors. The $197.6 billion market cap positions NONOF as a healthcare heavyweight, but recent declines signal market concerns about growth deceleration.
Dividend and Shareholder Returns
Novo Nordisk increased dividends 17.56% year-over-year, demonstrating confidence in cash flows. The $11.76 dividend per share and 4.14% yield attract income-focused investors. Management must balance dividend growth with R&D investments needed to maintain competitive positioning in obesity treatment markets.
Technical Setup
The stock shows RSI of 69.02, indicating overbought conditions, while MACD momentum remains positive. Bollinger Bands suggest the stock trades near upper resistance at $44.09, with support at $34.97. Volume remains light at 19,242 shares versus 257,311 average, suggesting limited conviction ahead of earnings.
Meyka AI Grade and Investment Outlook
Meyka AI rates NONOF with a grade of B+, reflecting balanced fundamentals amid growth uncertainty.
Grade Methodology
This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The B+ rating suggests NONOF offers reasonable value but faces execution risks. The company scores strongly on profitability metrics (ROE of 61.11% and ROA of 18.90%) but weaker on growth rates relative to peers. These grades are not guaranteed and we are not financial advisors.
What Investors Should Monitor
The May 6 earnings call will reveal management guidance on obesity market saturation, competitive pressures from Eli Lilly’s Mounjaro, and pipeline progress. Listen for commentary on manufacturing capacity, pricing strategies, and international expansion plans. Any guidance cuts or margin compression warnings could trigger sharp declines given the stock’s recent recovery. Conversely, strong obesity care growth and margin expansion could reignite investor enthusiasm and support valuations above $50 per share.
Final Thoughts
Novo Nordisk’s May 6 earnings report will test whether the company can sustain GLP-1 momentum and justify its $197.6 billion valuation. Trading 46% below its 52-week high at $44.35, the stock offers potential value if obesity care growth continues. Historical patterns suggest the company may beat EPS but miss revenue. Key focus areas include diabetes and obesity division performance, margin trends, and competitive guidance. The B+ Meyka AI grade reflects solid fundamentals with execution risks in an increasingly competitive pharmaceutical landscape.
FAQs
What are analysts expecting from Novo Nordisk’s May 6 earnings?
Analysts expect $0.925 EPS and $10.99 billion revenue, representing modest declines from recent quarters due to pharmaceutical market headwinds and obesity care competition.
Will NONOF beat or miss earnings estimates?
NONOF likely beats EPS but misses revenue. The company beat EPS in three of four recent quarters while missing revenue in two of four quarters.
Why did NONOF stock fall 46% from its 52-week high?
The decline reflects concerns about obesity care market saturation, increased competition from Eli Lilly, and slower-than-expected revenue growth with recent revenue misses.
What is the Meyka AI B+ grade and what does it mean?
The B+ grade reflects balanced fundamentals with strong profitability (61% ROE) but slower growth relative to peers, suggesting reasonable value with execution risks.
What should investors watch during the earnings call?
Monitor obesity care growth, Eli Lilly competition, margin trends, manufacturing capacity, and management guidance. Guidance cuts or margin compression could trigger sharp declines.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)